drugset / Trial / NCT00599820
Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks
Timeline
- Start
- 2005-11
- Primary completion
- 2005-11
- Completion
- 2006-05
Outcome
Outcome not reported
Stopped (Enrollment): “Poor accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 2.5 mg | Intravitreal |